111In-DOTA-HER3

N/A

Report date: 2025/10/30 15:24:42

Base Information

Drug Name111In-DOTA-HER3

Drug Alias NameN/A

ClassificationRadiation-emitting products > Nuclides > Indium > 111InRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionAnti-Receptor tyrosine-protein kinase erbB-3

TargetsReceptor tyrosine-protein kinase erbB-3

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesActinium Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesActinium Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A